Kabir et al. [371] identified a miR-7/TYRO3 axis that regulates the growth and invasiveness of sorafenib-resistant HCC cells, suggesting a potential therapeutic role for miR-7. Here, TYRO3 is linked to hepatocellular carcinoma.